Lorano

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lorano

Property Description
Active ingredient Loratadine (C22H23ClN2O2)
Form Tablet, syrup, orally-disintegrating tablets
Pharmacological class Second-generation H1-receptor antagonist
Common use Symptomatic relief of allergic conditions
Origin Synthetic, tricyclic derivative

What Type of Medicine is Lorano and What is its Composition?

Lorano is a pharmaceutical product containing the synthetic compound Loratadine as its single active ingredient. This agent is classified as a second-generation H1-receptor antagonist, a class recognized for its efficacy and improved safety profile compared to older compounds. This classification is critical because it signifies that Loratadine is specifically designed to target peripheral histamine receptors with minimal penetration of the blood-brain barrier, a structural feature that supports its non-sedating profile.

The brand Lorano is typically presented as a single-ingredient product, which includes Loratadine combined with essential non-active excipients such as lactose and maize starch to form the solid oral vehicle in the tablet. The presence of these excipients defines the physical characteristics of the tablet, differentiating it from the liquid syrup formulation. This singular focus on the Loratadine substance ensures that the product delivers a dedicated, long-acting anti-allergic effect.


Loratadine’s Physical Forms and General Purpose

The medication is intended for the oral route of administration and is available in several dosage forms, most commonly including the standard tablet and the liquid syrup, alongside specialized orally-disintegrating tablets. This availability of both solid and liquid forms is crucial for accommodating the target audience, specifically children over two years of age who may require the syrup, versus adults who primarily use the tablet.

The general purpose of Lorano is to provide symptomatic relief by acting as a competitive histamine antagonist. This mechanism helps alleviate the direct effects of histamine release, making the drug broadly used for reducing the irritations associated with typical allergic reactions. This includes neutralizing symptoms such as persistent sneezing, runny or itchy nose, itchy or burning eyes, and the manifestation of wheals in the skin, which commonly occur in conditions like allergic rhinitis and chronic urticaria.

What side effects are possible with Lorano?

The safety characteristics of Loratadine (Lorano) are officially classified by regulatory authorities based on the frequency and system-organ class of reported adverse reactions. The most frequently documented effects from clinical data are generally related to the Nervous System and general well-being.

Adverse Reaction Scope

Classification Examples of Officially Listed Adverse Reactions
Common (Reported ge 1/100 to < 1/10) Headache, somnolence (drowsiness), fatigue, dry mouth
Uncommon (Reported ge 1/1,000 to < 1/100) Insomnia, nervousness, dizziness, appetite increase
Very Rare (Reported < 1/10,000) Hypersensitivity reactions (including anaphylaxis), tachycardia, seizures, hepatic function abnormal, nausea, rash
Not Known (Cannot be estimated) Weight increased

Serious adverse reactions, which are classified as Very Rare, include severe hypersensitivity reactions like anaphylaxis and angioedema, as well as reports of seizures and abnormal hepatic function.

Safety Considerations for Specific Groups

Official labeling includes specific safety considerations for certain populations. The use of Loratadine is not established for children younger than 2 years of age. Patients with severe hepatic impairment are generally advised against using the medication or may require special caution due to the drug’s metabolism. Furthermore, the label advises that the medication should be discontinued at least 48 hours prior to allergy skin testing as the presence of the antihistamine may interfere with the test results.

Overdose and Emergency Response

The regulatory information for Lorano (Loratadine) overdose defines the expected clinical presentation and the required emergency response. Officially documented manifestations of overdosage include somnolence (drowsiness) and headache. A key physiological sign reported in these situations is tachycardia, representing a cardiovascular system response. An officially noted observation is the increased occurrence of anticholinergic symptoms following high exposures.

In the event of overdosage, regulatory documents mandate that individuals must seek immediate medical attention or contact a Poison Control Center right away. Urgent help is required based on the occurrence of any documented clinical signs or an accidental excessive intake.

For treatment, the official labeling specifies that general symptomatic and supportive measures must be instituted. Procedural interventions, such as the administration of activated charcoal as a slurry with water, may be attempted, and gastric lavage may be considered by medical professionals. No specific antidote is known for Loratadine. The substance is also stated to be not removed by haemodialysis, and it is not known if it is removed by peritoneal dialysis. Following any initial emergency stabilization, continued medical monitoring of the patient is required under official guidelines.

Therapeutic Uses of Lorano

What Lorano Treats: Main Uses and Benefits

Lorano (Loratadine) is commonly used to provide symptomatic relief in conditions characterized by periods of heightened symptoms due to allergic reactions. The medication supports the patient during difficult episodes by easing distress and helps improve day-to-day comfort during symptomatic periods.

Symptom Domains and Therapeutic Support

The primary therapeutic domains for Lorano are commonly understood to be seasonal and perennial allergic rhinitis and the supportive management of chronic idiopathic urticaria (hives). Lorano is relevant in contexts where additional symptomatic support is needed.

This medication is applied in addressing symptom clusters that may lead to temporary functional strain or discomfort, especially those linked to inhaled allergens. It is relevant for easing symptoms related to inflammatory or irritative states such as sneezing, runny nose, itchy, watery eyes, and skin itching (pruritus).

In clinical scenarios, Lorano is often used during phases when symptoms become more noticeable; it is relevant when supportive symptom management is appropriate for both acute episodes and recurrent manifestations. This application assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Itchy Skin and Nasal Discomfort Lorano is commonly used to help manage symptoms that create noticeable functional strain, particularly the combination of dermal itching and upper respiratory irritation.

Eligibility and Restrictions for Use

The official eligibility for using Lorano (Loratadine) is strictly defined by regulatory authorities based on population group, age, and health status.

Contraindications and Restrictions

Population Status Regulatory Classification
Absolute Contraindication Patients with known hypersensitivity to loratadine, desloratadine, or any component of the formulation [FDA Label; SmPC].
Conditional Use Patients with severe hepatic impairment or severe renal impairment; use may be permitted but often requires an adjusted, reduced dose due to altered clearance [SmPC].
Age Restriction Use is not established and not recommended in children under 2 years of age [FDA Label].
Lactation Status Use is not recommended in breastfeeding women as the drug is excreted in breast milk [SmPC].

Populations Allowed Under Standard Labeling

Lorano is approved for use in adults and adolescents (12 years of age and older). Eligibility is also established for children ge 6 years of age. In the younger pediatric group (children 2 to under 6 years), use is permitted but is typically limited to the liquid or syrup formulations [FDA Label]. Individuals with Phenylketonuria (PKU) must note that certain chewable or orally-disintegrating tablets contain phenylalanine [MedlinePlus].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lorano (loratadine) is metabolized primarily by specific enzymes in the liver, Cytochrome P450 3A4 (CYP3A4) and, to a lesser extent, CYP2D6. As a result, certain medications that inhibit these enzymes can significantly increase the concentration of loratadine and its active metabolite in the bloodstream.

Documented Pharmacokinetic Interactions

Interacting Medicine/Category Mechanism and Effect
Potent CYP3A4 Inhibitors (e.g., ketoconazole, erythromycin) Substantially increased plasma concentrations (AUC) of loratadine and desloratadine were observed.
CYP2D6 and CYP3A4 Inhibitors (e.g., cimetidine) Substantially increased plasma concentrations (AUC) of loratadine and desloratadine were observed.
Food Food may delay the absorption time and increase systemic exposure to loratadine.

Despite the significant increases in plasma levels observed in clinical studies with these inhibitors, no change in the overall safety profile, such as increased frequency of cardiac adverse effects, was noted.

Other Interaction-Related Constraints

Antihistamines are known to suppress the wheal and flare reaction, which can interfere with the results of diagnostic skin tests. It is necessary to stop taking Lorano at least 48 hours prior to any scheduled skin testing to ensure the accuracy of the results.

For patients with severe liver impairment or significantly decreased renal function (Glomerular Filtration Rate < 30 mL/ min), there is an increased risk of drug and metabolite accumulation. This population may require an initial dosage reduction to minimize this risk.

Mechanism of Action

Selective H1 Receptor Modulation

Lorano (loratadine) acts primarily within the domain of histamine-mediated signaling. Its core mechanism involves selective and competitive antagonism of the peripheral histamine H1 receptors . The compound binds to the H1 receptor, stabilizing its inactive conformational state and preventing the receptor's activation by the endogenous mediator, histamine. This molecular interaction results in the inhibition of immediate downstream signaling sequences that are typically initiated by histamine binding.


Modulation of Histamine-Induced Cellular Effects

The compound exhibits a prolonged half-life, supporting sustained receptor modulation. By decreasing the activation of the H1 receptor, Lorano modulates cellular processes affected by elevated inflammatory mediators. This action attenuates the histamine-induced signaling cascade that controls vascular permeability and subsequent perivascular fluid dynamics. This sequence of molecular and cellular events defines the resulting modulation of the physiological system, remaining within the domain of the pharmacodynamic effect.

Dosage and Administration Information

The administration guidelines for Lorano (Loratadine) establish parameters for its oral use based on age, physical formulation, and patient health status. The core usage principle is once-daily administration.

Standardized Dosing and Frequency

Population Standard Daily Dose Maximum Frequency
Adults and Children 6+ years 10 mg Once every 24 hours
Children 2–5 years 5 mg Once every 24 hours

The maximum dose for any individual over 6 years of age is limited to 10 mg in a 24-hour period.


Special Administration Conditions

Administration of Lorano is flexible regarding food, and the medicine may be taken without regard to mealtime. However, specific procedural adjustments are indicated for certain patient groups:

  • Impaired Function: Individuals with severe hepatic or renal impairment (GFR < 30 mL/min) follow a reduced frequency protocol, administering the standard dose every other day to manage systemic exposure.
  • Procedural Constraint: All administration of Lorano must be discontinued for at least 48 hours prior to a scheduled allergy skin-prick test.

Standard tablets must be swallowed whole, whereas orally-disintegrating tablets are intended to dissolve on the tongue and do not require water. This structured protocol dictates the method, frequency, and condition of use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lorano (Loratadine)

This overview summarizes the research conducted on Lorano, focusing on study design, measured outcomes, and the known limitations within the evidence base, without offering clinical guidance or recommendations.


Evidence for Use in Allergic Rhinitis (Hay Fever and Related Nasal Allergies)

Research exploring Lorano was evaluated in controlled scientific investigations for allergic rhinitis—a condition characterized by fluctuating or episodic manifestations. Researchers conducted numerous short-term, randomized, double-blind trials, including comparisons against inactive controls (placebo) and some other H1-antagonists.

The main outcomes monitored were patient-reported symptom scores, specifically the Total Nasal Symptom Scores (TNSS) and Total Ocular Symptom Scores (TOSS), which quantify symptoms like sneezing and itchy, watery eyes. Studies reported findings that differed when compared to measurements recorded in the inactive control groups. Comparative studies described patterns of measured change in symptom scores that were observed across Loratadine and certain other compared agents.

Evidence for Use in Chronic Idiopathic Urticaria (Chronic Hives)

For chronic idiopathic urticaria (CIU), research includes short-term, placebo-controlled clinical trials. These studies involved populations experiencing conditions involving periods of heightened symptoms of unknown origin. The primary outcomes monitored were related to the physical manifestations of the condition, exploring metrics such as pruritus (skin itching) and recording changes in the number and size of wheals (hives). Findings in the groups that received Loratadine were reported as differing from the measurements in the placebo groups.


Limitations and Areas for Further Research

The research landscape includes certain acknowledged structural limitations. While the data obtained from the comparisons against placebo is characterized by high methodological consistency, comparative evidence is lacking for certain aspects against other antihistamines. Follow-up durations were limited in the primary trials, meaning that long-term effects are not fully established. Data for very young children remain lower in volume compared to the adult population.

Key Studies & References Antihistamines and allergy - Australian Prescriber - Therapeutic Guidelines

Frequently Asked Questions (FAQ)

Common questions about Lorano (FAQ)


Q: How quickly should I expect Lorano to start working?

A: Studies and official product information indicate that the relief of allergy symptoms typically begins relatively quickly, often starting within 1 to 3 hours after administration. The medication is designed to provide sustained relief throughout the day.


Q: How long do the effects of Lorano usually last?

A: According to the official product information, Lorano is classified as a long-acting antihistamine. This medicine is designed to provide symptomatic relief for a period of up to 24 hours, which supports its typical once-daily dosing regimen.


Q: Can Lorano be taken at any time of day?

A: The medication is taken once daily, and the specific time of day is generally flexible. Official regulatory information also states that it may be taken with or without food, offering flexibility for use in different daily routines.


Q: Is Lorano the same type of medicine as Claritin?

A: Yes, regulatory documents confirm that Loratadine is the active ingredient in the medication Lorano. Loratadine is also the active ingredient in the brand-name medicine Claritin, as well as many other generic versions. All are second-generation antihistamines.


Q: Is there a generic version of Lorano available?

A: Loratadine, the active substance in Lorano, is widely available as a generic medicine in many markets globally. This availability is due to specific regulatory approvals for generic versions of the drug.


Q: What happens if I forget to take my Lorano dose?

A: Product information generally advises that a missed dose may be taken when remembered. It is important to note that the established maximum daily dose should not be exceeded, meaning no more than one dose should be taken in a 24-hour period.


Q: Is it possible to take too much Lorano by accident?

A: Taking more than the recommended amount may lead to side effects such as increased drowsiness. Regulatory warnings indicate that if an overdose is suspected, emergency medical assistance should be sought.


Q: Can Lorano be used for hives or skin rashes?

A: Regulatory documents indicate that Lorano is specifically approved for the treatment of symptoms associated with chronic idiopathic urticaria, a condition often involving persistent hives. Its use is focused on treating symptoms related to this allergic condition.


Q: Can Lorano cause changes in heart rate or rhythm?

A: Very rare adverse effects, such as tachycardia (fast heart rate) or palpitations, have been included in safety listings. However, extensive safety reviews have generally indicated that a direct link between Lorano use and serious abnormal heart rhythms is not typically established.


Q: Are there long-term side effects associated with taking Lorano regularly?

A: Official information classifies side effects based on reports from short-term clinical trials, with common effects including headache, fatigue, and somnolence. Long-term effects beyond the duration of these initial trials are not fully established. Patients who experience any new or persistent effects are advised to consult with a qualified health professional.


Q: Do children experience different side effects from Lorano than adults?

A: Reported adverse effects in children from clinical studies are generally similar to those observed in adults. However, in some pediatric studies, effects such as nervousness, wheezing, and fatigue were reported at slightly higher frequencies than in placebo groups.


Q: Why are there different strengths of Lorano available?

A: Different strengths, such as the 5 mg and 10 mg formulations, are necessary to align with the different established maximum daily doses. These doses are set for specific age groups, such as younger children versus adolescents and adults.


Q: Can Lorano cause stomach upset or nausea?

A: Gastrointestinal effects, such as dry mouth, are listed as common side effects. While nausea and gastritis have been reported in regulatory safety data, they are classified as very rare adverse effects.


Q: Does Lorano interact with high blood pressure medication?

A: Official drug labels list certain enzyme inhibitors that can affect Lorano's concentration, but they do not specifically contraindicate its use with common high blood pressure medications. Lorano is an antihistamine, which is a different class of medicine.


Q: Can Lorano be crushed or should it be swallowed whole?

A: Standard Lorano tablets are formulated to be swallowed whole. Orally disintegrating tablets are designed to dissolve on the tongue. Generally, crushing standard tablets is not advised, especially since licensed liquid formulations are available.


Q: Are there warnings about using Lorano with herbal supplements?

A: Specific research on the interaction between Lorano and herbal supplements is limited in official regulatory documents. However, general guidance suggests that any herbal supplements, particularly those with the potential for sedative effects, should be noted to a healthcare provider, as antihistamines may potentially enhance those effects. Consultation with a qualified healthcare provider is advised.


Q: Does Lorano contain gluten or lactose?

A: Many Lorano tablets contain lactose monohydrate as an inactive ingredient, or excipient. While many labels explicitly state that the product is gluten-free, individuals with dietary restrictions are encouraged to check the inactive ingredients list of the specific formulation they intend to use.


Q: Does Lorano show up on standard drug tests?

A: Loratadine is typically not a substance that is screened for in standard workplace or legal drug testing panels. It is often included on lists of approved over-the-counter medications that do not usually interfere with these tests.


Q: Why do some people take Lorano even if they don't have seasonal allergies?

A: Official regulatory information confirms that Lorano is approved for two main conditions. In addition to symptoms of seasonal allergic rhinitis (hay fever), it is also indicated for the relief of symptoms associated with chronic idiopathic urticaria (chronic hives).


Q: Will taking Lorano help with a runny nose and sneezing?

A: Yes, regulatory product labeling indicates that Lorano is used for the temporary relief of symptoms due to hay fever and other upper respiratory allergies. These symptoms specifically include both sneezing and a runny nose.


Q: Can Lorano be used for allergic eye symptoms?

A: Yes, Lorano is indicated for the temporary relief of symptoms associated with upper respiratory allergies, which often include itchy, watery eyes. The medicine works to address both the nasal and ocular manifestations of these allergies.


Q: How does Lorano work to treat indoor versus outdoor allergies?

A: The official label indicates Lorano is used for both Indoor and Outdoor Allergies. Its mechanism of action blocks the chemical histamine, which is released by the body in response to any trigger, whether it is an indoor allergen (like dust) or an outdoor allergen (like pollen).


Q: Is it possible to have an allergic reaction to Lorano itself?

A: The official warning section advises against using the medication if a person has a known allergy or hypersensitivity to the drug or any of its inactive components. Though very rare, severe allergic reactions, such as anaphylaxis, have been reported in safety data.


Q: Can Lorano help with chronic stuffiness?

A: Lorano, as an antihistamine, primarily targets symptoms like runny nose, sneezing, and itching. For relief of significant nasal congestion or stuffiness, a different type of drug called a decongestant is typically used, sometimes in a combination product.


Q: What is the difference between Lorano and a decongestant?

A: Lorano is an antihistamine that works by blocking the body's reaction to histamine, thereby relieving symptoms like sneezing and itching. A decongestant is a distinct class of medicine that acts to shrink swollen blood vessels in the nasal passages, specifically relieving nasal stuffiness.


Q: Do I need a prescription from a doctor to buy Lorano?

A: Loratadine, the active ingredient, is widely available as an over-the-counter (OTC) medication in many jurisdictions. Consequently, a prescription is not typically required to purchase the standard-strength single-ingredient tablets or liquid formulations.


Q: How long has Lorano been on the market?

A: Loratadine has a well-established history. While it was initially available as a prescription drug, it was approved for widespread over-the-counter use in markets like the U.S. in the early 2000s, making it a familiar and well-studied medication.


Q: Is it necessary to take Lorano every day during allergy season?

A: Lorano is a once-daily medicine used to temporarily relieve allergy symptoms. It may be taken daily during peak allergy season for continuous relief or may be used on an as-needed basis when symptoms are present, depending on the individual's needs.


Q: What are some reasons someone might be advised not to use Lorano?

A: Official regulatory warnings advise against using the medication if a person has a known allergy to the drug or its components. Additionally, special caution or dose adjustment is often required for children under 2 years of age and for individuals with severe liver or kidney impairment.


Q: What kinds of allergies is Lorano typically used for?

A: Regulatory information indicates Lorano is used for symptoms of hay fever and other upper respiratory allergies. This covers reactions to common airborne allergens, including pollen, dust, mold, and animal dander, often summarized as 'Indoor and Outdoor Allergies'.

How should Lorano be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Lorano — Official Regulatory Information

Requirement Details (Strictly from Regulatory Labeling)
Labeled storage temperature requirements Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with excursions permitted to 15 C to 30 C (59 F to 86 F) [1.6, 2.7].
Light/moisture protection requirements Store away from excess heat and moisture and direct light [2.3, 2.5].
Packaging-related storage rules Keep medication in the original container and ensure the container is tightly closed [1.3, 2.3].
Child-protection storage requirements Keep out of the sight and reach of children [1.3, 2.1]. Always lock safety caps [2.3].
Disposal instructions Do not use this medicine after the expiry date [1.3]. Do not throw away medicines via wastewater or household waste; consult a pharmacist for disposal guidance [1.3].

Official storage documents mandate keeping Lorano at controlled room temperature, forbidding storage above 30 C or freezing, and requiring protection from light and moisture. The drug must remain in its original, tightly closed container to maintain stability. Disposal instructions strictly require that the medication not be discarded in household trash or down the drain, instead directing the user to ask a pharmacist how to properly discard unused or expired product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lorano found in:

A-Z Index: